title: Inner-city tuberculosis in the USA.
abstract: Tuberculosis (TB) has become more common during the past five years in several areas of the USA. Occurrence has been facilitated by the increasing number of patients with concurrent HIV infection, by cases due to multiple-drug-resistant strains, by incomplete TB therapy among homeless and non-compliant patients, and by cases in immigrants from other countries where TB prevalence is high. These features mean that the major burden of TB today is being borne by inner-city health care facilities that care for the poor. This is illustrated by data from Atlanta, Georgia, where a large proportion of the new cases recognized in the metropolitan area are reported by Grady Memorial Hospital, the public hospital serving the indigent and working poor of the inner city. Similar patterns are recognized in the other USA cities where TB has again become a blight. In view of these epidemiological features, minimizing inner-city TB will require careful attention to diagnosis and isolation procedures in the hospital. Engineering changes at hospitals providing acute care of TB have recently been ordered by the federal government. These promise to be very expensive, and primarily affect the public hospitals, which can least afford them. Innovative treatment programmes are essential, as follow-up after acute care is difficult in this setting. Directly observed therapy can help, but for some cases the era of the TB hospital may have returned. Current attention focuses on legal and ethical issues associated with detaining non-compliant and recalcitrant patients to complete their therapy. Bacille Calmette Guerin (BCG) vaccine is not a priority for this setting at this time.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia.
authors.forename: J E
authors.initials: JE
authors.lastname: McGowan
authors.forename: H M
authors.initials: HM
authors.lastname: Blumberg
mesh_terms: D017088:AIDS-Related Opportunistic Infections; D000995:Antitubercular Agents / Q000627:therapeutic use; D001500:BCG Vaccine; D017714:Community-Acquired Infections / Q000453:epidemiology* / Q000517:prevention & control; D003428:Cross Infection / Q000517:prevention & control; D005845:Georgia / Q000453:epidemiology; D006703:Ill-Housed Persons; D006779:Hospitals, Public / Q000191:economics; D006801:Humans; D010349:Patient Compliance; D014376:Tuberculosis / Q000453:epidemiology* / Q000517:prevention & control; D018088:Tuberculosis, Multidrug-Resistant / Q000453:epidemiology; D014505:Urban Population
chemical_list: D000995:Antitubercular Agents; D001500:BCG Vaccine